Cost-Effectiveness Analysis of a Three-Drug Regimen Containing Bevacizumab for the Treatment of Recurrent Pediatric Medulloblastoma in China: Based on a COG Randomized Phase II Screening Trial

BACKGROUND: Medulloblastoma is the most common malignant brain tumor of childhood, accounting for 6 to 7 percent of all childhood CNS tumors. The purpose of this study was to evaluate the economic efficacy of a bevacizumab combined with temozolomide + irinotecan regimen for the treatment of recurren...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Zhaoyan, Tian, Fangyuan, Chen, Xi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Public Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9201059/
https://www.ncbi.nlm.nih.gov/pubmed/35719637
http://dx.doi.org/10.3389/fpubh.2022.914536

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9201059/
https://www.ncbi.nlm.nih.gov/pubmed/35719637
http://dx.doi.org/10.3389/fpubh.2022.914536

Ejemplares similares